XML 59 R47.htm IDEA: XBRL DOCUMENT v3.21.1
License Agreements - Lilly (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 136 Months Ended
May 31, 2019
Mar. 31, 2016
Jul. 31, 2010
Dec. 31, 2009
Mar. 31, 2021
Mar. 31, 2020
Mar. 31, 2021
License agreements              
Research and Development Expense         $ 306,896 $ 1,085,287  
Revenues         604,718 568,507  
Product royalty revenues              
License agreements              
Revenues         $ 99,907 81,780  
Eli Lilly              
License agreements              
Upfront payment received under license agreement       $ 90,000      
Eli Lilly | Phase IIB              
License agreements              
Associated future global development costs from the initiation of a Phase IIb trial, if elected to co-develop (as a percentage)     30.00%   30.00%    
Eli Lilly | Pre-specified Events | Maximum              
License agreements              
Upfront and immediate milestone payment to be received under license agreement       665,000      
Eli Lilly | Development Milestones              
License agreements              
Amount recognized and received for the achievement of a predefined milestone             $ 149,000
Eli Lilly | Development Milestones | Maximum              
License agreements              
Upfront and immediate milestone payment to be received under license agreement       150,000      
Eli Lilly | Regulatory Milestones              
License agreements              
Amount recognized and received for the achievement of a predefined milestone             $ 265,000
Eli Lilly | Regulatory Milestones | Maximum              
License agreements              
Upfront and immediate milestone payment to be received under license agreement       365,000      
Eli Lilly | Sales and Commercial Milestones              
License agreements              
Revenues         $ 32,300 25,400  
Eli Lilly | Sales and Commercial Milestones | Maximum              
License agreements              
Upfront and immediate milestone payment to be received under license agreement       $ 150,000      
Royalty payments on future global net sales (as a percent)         20.00%    
Eli Lilly | Development and Commercialization Milestones              
License agreements              
Revenues         $ 0 $ 0  
Eli Lilly | GVHD              
License agreements              
Upfront payment under license agreement   $ 35,000          
Additional milestone payments under the license agreement   $ 40,000          
Eli Lilly | GVHD | Regulatory Milestones              
License agreements              
Milestone payment made under license agreement $ 20,000